Drug Combination May Become New Standard Treatment for Advanced Kidney Cancer (VIDEO)

Dana-Farber Cancer Institute

Caption

Toni K. Choueiri, MD details encouraging findings on the combination of the immunotherapy drug avelumab plus axitinib, a targeted agent, in treating advanced kidney cancer.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.